Feasibility of re‐biopsy and <i>EGFR</i> mutation analysis in patients with non‐small cell lung cancer

Abstract

Re-biopsy in advanced NSCLC is feasible in real world clinical practice, particularly in younger patients and those who achieved a previous response to EGFR-TKIs.